Please try another search
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company, engages in developing and preparing to commercialize a fast-acting sublingual thin film for debilitating OFF episodes associated with Parkinson’s disease (PD). The company’s drug candidate includes APL-130277, an easy-to-administer, sublingual thin film formulation of apomorphine that has completed a Phase II clinical trial for the treatment of OFF episodes for advanced PD patients. It has collaboration with The Michael J. Fox Foundation for Parkinson's research. The company was formerly known as Cannasat Therapeutics Inc. and changed its name to Cynapsus Therapeutics Inc. in April 2010. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada. As of October 21, 2016, Cynapsus Therapeutics Inc. operates as a subsidiary of Sunovion CNS Development Canada ULC.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review